UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended October 1, 2023
OR
TRANSITION REPORT PURSUANT TO SECTION 13
OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from _______ to _______
COMMISSION FILE NUMBER 1-3619
----
PFIZER INC.
(Exact name of registrant as specified in its charter)
Delaware13-5315170
(State of Incorporation)(I.R.S. Employer Identification No.)
66 Hudson Boulevard East, New York, New York 10001-2192
(Address of principal executive offices) (zip code)
(212) 733-2323
(Registrant s telephone number including area code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, $0.05 par valuePFENew York Stock Exchange
1.000% Notes due 2027PFE27New York Stock Exchange
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
YesxNo
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T ( 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
YesxNo
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company, and emerging growth company in Rule 12b-2 of the Exchange Act:
Large Accelerated filer x Accelerated filer Non-accelerated filer Smaller reporting company Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes Nox
At November 3, 2023, 5,646,413,292 shares of the issuer s voting common stock were outstanding.
TABLE OF CONTENTS
PART I. FINANCIAL INFORMATION
Page
Item 1.
Financial Statements
Condensed Consolidated Statements of Operations
Condensed Consolidated Statements of Comprehensive Income/(Loss)
Condensed Consolidated Balance Sheets
Condensed Consolidated Statements of Equity
Condensed Consolidated Statements of Cash Flows
Notes to Condensed Consolidated Financial Statements
10
Item 2.
Management s Discussion and Analysis of Financial Condition and Results of Operations
40
Item 3.
Quantitative and Qualitative Disclosures About Market Risk
61
Item 4.
Controls and Procedures
61
PART II. OTHER INFORMATION
Item 1.
Legal Proceedings
62
Item 1A.
Risk Factors
62
Item 2.
Unregistered Sales of Equity Securities and Use of Proceeds
63
Item 3.
Defaults Upon Senior SecuritiesN/A
Item 4.
Mine Safety DisclosuresN/A
Item 5.
Other Information63
Item 6.
Exhibits
63
Signature
64
N/A = Not Applicable
DEFINED TERMS
Unless the context requires otherwise, references to Pfizer, the Company, we, us or our in this Form 10-Q (defined below) refer to Pfizer Inc. and its subsidiaries. Pfizer s fiscal quarter-end for subsidiaries operating outside the U.S. is as of and for the three and nine months ended August 27, 2023 and August 28, 2022, and for U.S. subsidiaries is as of and for the three and nine months ended October 1, 2023 and October 2, 2022. References to Notes in this Form 10-Q are to the Notes to the Condensed or Consolidated Financial Statements in this Form 10-Q or in our 2022 Form 10-K. We also have used several other terms in this Form 10-Q, most of which are explained or defined below:
2022 Form 10-K
Annual Report on Form 10-K for the fiscal year ended December 31, 2022
AlexionAlexion Pharma International Operations Limited, a subsidiary of AstraZeneca PLC
ALKanaplastic lymphoma kinase
Alliance revenuesRevenues from alliance agreements under which we co-promote products discovered or developed by other companies or us
ArenaArena Pharmaceuticals, Inc.
ArvinasArvinas, Inc.
AstellasAstellas Pharma Inc., Astellas US LLC and Astellas Pharma US, Inc.
ATTR-CMtransthyretin amyloid cardiomyopathy
BiohavenBiohaven Pharmaceutical Holding Company Ltd.
BioNTechBioNTech SE
BiopharmaGlobal Biopharmaceuticals Business
BlackstoneBlackstone Life Sciences
BMSBristol-Myers Squibb Company
BODBoard of Directors
CDCU.S. Centers for Disease Control and Prevention
Comirnaty*Unless otherwise noted, refers to, as applicable, and as authorized or approved, the Pfizer-BioNTech COVID-19 Vaccine, the Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5), Comirnaty (COVID-19 Vaccine, mRNA, 2023-2024 Formula), the Pfizer-BioNTech COVID-19 Vaccine (2023-2024 Formula), Comirnaty Original/Omicron BA.1, Comirnaty Original/Omicron BA.4/BA.5 and Comirnaty XBB.1.5.
Consumer Healthcare JVGSK Consumer Healthcare JV
COVID-19novel coronavirus disease of 2019
Developed EuropeIncludes the following markets: Western Europe, Scandinavian countries and Finland
Developed MarketsIncludes the following markets: U.S., Developed Europe, Japan, Australia, Canada, South Korea and New Zealand
Developed Rest of WorldIncludes the following markets: Japan, Canada, Australia, South Korea and New Zealand
ECEuropean Commission
EMAEuropean Medicines Agency
Emerging MarketsIncludes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Eastern Europe, Central Europe, the Middle East, Africa and Turkey
EPS
earnings per share
ESGEnvironmental, Social and Governance
EUEuropean Union
EUAemergency use authorization
Exchange ActSecurities Exchange Act of 1934, as amended
FASBFinancial Accounting Standards Board
FDAU.S. Food and Drug Administration
Form 10-QThis Quarterly Report on Form 10-Q for the quarterly period ended October 1, 2023
GAAPGenerally Accepted Accounting Principles
GBTGlobal Blood Therapeutics, Inc.
GSKGSK plc
HaleonHaleon plc
HIPAAHealth Insurance Portability and Accountability Act of 1996
HospiraHospira, Inc.
IPR&Din-process research and development
IRAInflation Reduction Act of 2022
IRSU.S. Internal Revenue Service
JAKJanus kinase
JVjoint venture
KingKing Pharmaceuticals LLC (formerly King Pharmaceuticals, Inc.)
LIBORLondon Interbank Offered Rate
LOEloss of exclusivity
LPS
loss per share
mCRCmetastatic colorectal cancer
mCRPCmetastatic castration-resistant prostate cancer
mCSPCmetastatic castration-sensitive prostate cancer
MD&AManagement s Discussion and Analysis of Financial Condition and Results of Operations
MDLMulti-District Litigation
MeridianMeridian Medical Technologies, Inc.
Moody sMoody s Investors Service
mRNAmessenger ribonucleic acid
MSAManufacturing Supply Agreement
MylanMylan N.V.
NDA
New Drug Application
NimbusNimbus Therapeutics, LLC
nmCRPCnon-metastatic castration-resistant prostate cancer
NSCLCnon-small cell lung cancer
ODToral disintegrating tablet
OnoOno Pharmaceutical Co., Ltd.
OPKOOPKO Health, Inc.
OTCover-the-counter
Paxlovid*an oral COVID-19 treatment (nirmatrelvir tablets and ritonavir tablets)
PC1Pfizer CentreOne
PharmaciaPharmacia LLC (formerly Pharmacia Corporation)
PIEPfizer Investment Enterprises Pte. Ltd. (a wholly-owned finance subsidiary of Pfizer)
Prevnar familyIncludes Prevnar 13/Prevenar 13 (pediatric and adult) and Prevnar 20/Apexxnar (pediatric and adult)
PsApsoriatic arthritis
QTDQuarter-to-date or three months ended
RArheumatoid arthritis
RCCrenal cell carcinoma
R&Dresearch and development
RSVrespiratory syncytial virus
S&PStandard & Poor s
SeagenSeagen Inc.
SECU.S. Securities and Exchange Commission
SI&Aselling, informational and administrative
TSAstransition service arrangements
UCulcerative colitis
U.K.United Kingdom
U.S.United States
Upjohn BusinessPfizer s former global, primarily off-patent branded and generics business, which included a portfolio of 20 globally recognized solid oral dose brands, including Lipitor, Lyrica, Norvasc, Celebrex and Viagra, as well as a U.S.-based generics platform, Greenstone, that was spun-off on November 16, 2020 and combined with Mylan to create Viatris
ViatrisViatris Inc.
ViiVViiV Healthcare Limited
Vyndaqel familyIncludes Vyndaqel, Vyndamax and Vynmac
WRDMWorldwide Research, Development and Medical
YTDYear-to-date or nine months ended
*The Pfizer-BioNTech COVID-19 Vaccine (2023-2024 Formula) and certain uses of Paxlovid have not been approved or licensed by the FDA. The Pfizer-BioNTech COVID-19 Vaccine (2023-2024 Formula) has been authorized by the FDA under an EUA to prevent COVID-19 in individuals aged 6 months through 11 years of age. Paxlovid has been authorized for emergency use by the FDA under an EUA for the treatment of mild-to-moderate COVID-19 in pediatric patients (12 years of age and older weighing at least 40 kg) who are at high risk for progression to severe COVID-19, including hospitalization or death. The emergency uses are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product during the COVID-19 pandemic under Section 564(b)(1) of the U.S. Federal Food, Drug and Cosmetic Act unless the declaration is terminated or authorization revoked sooner. Please see the EUA Fact Sheets at www.covid19oralrx.com and www.cvdvaccine-us.com.
This Form 10-Q includes discussion of certain clinical studies relating to various in-line products and/or product candidates. These studies typically are part of a larger body of clinical data relating to such products or product candidates, and the discussion herein should be considered in the context of the larger body of data. In addition, clinical trial data are subject to differing interpretations, and, even when we view data as sufficient to support the safety and/or effectiveness of a product candidate or a new indication for an in-line product, regulatory authorities may not share our views and may require additional data or may deny approval altogether.
Some amounts in this Form 10-Q may not add due to rounding. All percentages have been calculated using unrounded amounts. All trademarks mentioned are the property of their owners.
The information contained on our website, our Facebook, Instagram, YouTube and LinkedIn pages or our Twitter accounts, or any third-party website, is not incorporated by reference into this Form 10-Q.
PART I. FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS
PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(UNAUDITED)
Three Months EndedNine Months Ended
(MILLIONS, EXCEPT PER SHARE DATA)October 1,
2023October 2,
2022October 1,
2023October 2,
2022
Revenues$13,232 $22,638 $44,247 $76,040
Costs and expenses:
Cost of sales(a), (b)
9,269 6,063 17,391 24,696
Selling, informational and administrative expenses(a)
3,281 3,391 10,196 9,032
Research and development expenses(a)
2,711 2,696 7,864 7,813
Acquired in-process research and development expenses67 524 122 880
Amortization of intangible assets1,179 822 3,466 2,478
Restructuring charges and certain acquisition-related costs155 199 377 580
Other (income)/deductions net(79)(59)(356)1,063
Income/(loss) from continuing operations before provision/(benefit) for taxes on income/(loss)
(3,352)9,001 5,187 29,498
Provision/(benefit) for taxes on income/(loss)
(964)356 (320)3,098
Income/(loss) from continuing operations
(2,388)8,645 5,507 26,400
Discontinued operations net of tax12 (21)11 4
Net income/(loss) before allocation to noncontrolling interests
(2,376)8,623 5,518 26,404
Less: Net income attributable to noncontrolling interests6 15 30 27
Net income/(loss) attributable to Pfizer Inc. common shareholders
$(2,382)$8,608 $5,488 $26,378
Earnings/(loss) per common share basic:
Income/(loss) from continuing operations attributable to Pfizer Inc. common shareholders
$(0.42)$1.54 $0.97 $4.70
Discontinued operations net of tax
Net income/(loss) attributable to Pfizer Inc. common shareholders
$(0.42)$1.54 $0.97 $4.71
Earnings/(loss) per common share diluted:
Income/(loss) from continuing operations attributable to Pfizer Inc. common shareholders
$(0.42)$1.51 $0.96 $4.60
Discontinued operations net of tax
Net income/(loss) attributable to Pfizer Inc. common shareholders
$(0.42)$1.51 $0.96 $4.60
Weighted-average shares basic5,646 5,607 5,642 5,606
Weighted-average shares diluted5,646 5,718 5,714 5,729
(a)Exclusive of amortization of intangible assets.
(b)See Notes 8 and 13.
See Accompanying Notes.
PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME/(LOSS)
(UNAUDITED)
Three Months EndedNine Months Ended
(MILLIONS)October 1,
2023October 2,
2022October 1,
2023October 2,
2022
Net income/(loss) before allocation to noncontrolling interests
$(2,376)$8,623 $5,518 $26,404
Foreign currency translation adjustments, net(109)(918)234 (2,549)
Unrealized holding gains/(losses) on derivative financial instruments, net408 589 519 1,443
Reclassification adjustments for (gains)/losses included in net income/(loss)(a)
(67)(615)73 (972)
341 (26)593 471
Unrealized holding gains/(losses) on available-for-sale securities, net(83)(777)30 (1,397)
Reclassification adjustments for (gains)/losses included in net income/(loss)(b)
51 606 (442)1,094
(32)(171)(411)(303)
Reclassification adjustments related to amortization of prior service costs and other, net(29)(31)(88)(99)
Reclassification adjustments related to curtailments of prior service costs and other, net(1)2 (14)(8)
(30)(29)(102)(107)
Other comprehensive income/(loss), before tax170 (1,144)313 (2,488)
Tax provision/(benefit) on other comprehensive income/(loss)36 (33)(17)(149)
Other comprehensive income/(loss) before allocation to noncontrolling interests$134 $(1,111)$330 $(2,339)
Comprehensive income/(loss) before allocation to noncontrolling interests$(2,242)$7,512 $5,848 $24,065
Less: Comprehensive income/(loss) attributable to noncontrolling interests4 10 23 16
Comprehensive income/(loss) attributable to Pfizer Inc.$(2,247)$7,503 $5,826 $24,049
(a)Reclassified into Other (income)/deductions net and Cost of sales. See Note 7E.
(b)Reclassified into Other (income)/deductions net.
See Accompanying Notes.
PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(MILLIONS)October 1,
2023December 31, 2022
(Unaudited)
Assets
Cash and cash equivalents$3,148 $416
Short-term investments41,033 22,316
Trade accounts receivable, less allowance for doubtful accounts: 2023 $465; 2022 $449
11,086 10,952
Inventories10,204 8,981
Current tax assets3,917 3,577
Other current assets4,624 5,017
Total current assets74,012 51,259
Equity-method investments11,025 11,033
Long-term investments3,214 4,036
Property, plant and equipment, less accumulated depreciation: 2023 $15,779; 2022 $15,174
17,862 16,274
Identifiable intangible assets40,224 43,370
Goodwill51,527 51,375
Noncurrent deferred tax assets and other noncurrent tax assets8,350 6,693
Other noncurrent assets8,808 13,163
Total assets$215,021 $197,205
Liabilities and Equity
Short-term borrowings, including current portion of long-term debt: 2023 $2,260; 2022 $2,560
$2,548 $2,945
Trade accounts payable5,338 6,809
Dividends payable 2,303
Income taxes payable1,898 1,587
Accrued compensation and related items2,372 3,407
Deferred revenues2,204 2,520
Other current liabilities16,776 22,568
Total current liabilities31,136 42,138
Long-term debt61,048 32,884
Pension and postretirement benefit obligations2,166 2,250
Noncurrent deferred tax liabilities1,125 1,023
Other taxes payable8,099 9,812
Other noncurrent liabilities14,242 13,180
Total liabilities117,817 101,288
Commitments and Contingencies
Common stock478 476
Additional paid-in capital92,496 91,802
Treasury stock(114,485)(113,969)
Retained earnings126,411 125,656
Accumulated other comprehensive loss(7,966)(8,304)
Total Pfizer Inc. shareholders equity96,934 95,661
Equity attributable to noncontrolling interests270 256
Total equity97,204 95,916
Total liabilities and equity$215,021 $197,205
See Accompanying Notes.
PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED STATEMENTS OF EQUITY
(UNAUDITED)
PFIZER INC. SHAREHOLDERS
Common StockTreasury Stock
(MILLIONS, EXCEPT PER SHARE DATA)SharesPar ValueAdd l
Paid-In CapitalSharesCostRetained EarningsAccum. Other Comp.
LossShare-
holders EquityNon-controlling interestsTotal Equity
Balance, July 2, 20239,561 $478 $92,329 (3,916)$(114,482)$128,796 $(8,102)$99,019 $274 $99,293
Net income/(loss)
(2,382)(2,382)6 (2,376)
Other comprehensive income/(loss), net of tax
135 135 (2)134
Cash dividends declared, per share: $
Common stock
Noncontrolling interests (8)(8)
Share-based payment transactions1 167 (4)(2)161 161
Other
Balance, October 1, 20239,562 $478 $92,496 (3,916)$(114,485)$126,411 $(7,966)$96,934 $270 $97,204
PFIZER INC. SHAREHOLDERS
Common StockTreasury Stock
(MILLIONS, EXCEPT PER SHARE DATA)SharesPar ValueAdd l
Paid-In CapitalSharesCostRetained EarningsAccum. Other Comp.
LossShare-
holders EquityNon-controlling interestsTotal Equity
Balance, July 3, 20229,496 $476 $91,183 (3,903)$(113,939)$116,608 $(7,119)$87,208 $261 $87,469
Net income/(loss)
8,608 8,608 15 8,623
Other comprehensive income/(loss), net of tax(1,106)(1,106)(5)(1,111)
Cash dividends declared, per share: $0.40
Common stock (2,245)(2,245)(2,245)
Noncontrolling interests (7)(7)
Share-based payment transactions20 172 (6)(5)161 161
Other4 4 (4)
Balance, October 2, 20229,515 $476 $91,359 (3,903)$(113,945)$122,967 $(8,225)$92,631 $259 $92,891
PFIZER INC. SHAREHOLDERS
Common StockTreasury Stock
(MILLIONS, EXCEPT PER SHARE DATA)SharesPar ValueAdd l
Paid-In CapitalSharesCostRetained EarningsAccum. Other Comp.
LossShare-
holders EquityNon-controlling interestsTotal Equity
Balance, January 1, 20239,519 $476 $91,802 (3,903)$(113,969)$125,656 $(8,304)$95,661 $256 $95,916
Net income/(loss)
5,488 5,488 30 5,518
Other comprehensive income/(loss), net of tax338 338 (8)330
Cash dividends declared, per share: $0.82
Common stock(4,629)(4,629)(4,629)
Noncontrolling interests (8)(8)
Share-based payment transactions43 2 694 (12)(516)(104)77 77
Other
Balance, October 1, 20239,562 $478 $92,496 (3,916)$(114,485)$126,411 $(7,966)$96,934 $270 $97,204
PFIZER INC. SHAREHOLDERS
Common StockTreasury Stock
(MILLIONS, EXCEPT PER SHARE DATA)SharesPar ValueAdd l
Paid-In CapitalSharesCostRetained EarningsAccum. Other Comp.
LossShare-
holders EquityNon-controlling interestsTotal Equity
Balance, January 1, 20229,471 $473 $90,591 (3,851)$(111,361)$103,394 $(5,897)$77,201 $262 $77,462
Net income/(loss)
26,378 26,378 27 26,404
Other comprehensive income/(loss), net of tax(2,328)(2,328)(11)(2,339)
Cash dividends declared, per share: $1.20
Common stock (6,734)(6,734)(6,734)
Noncontrolling interests (7)(7)
Share-based payment transactions45 2 760 (12)(584)(71)108 108
Purchases of common stock(39)(2,000)(2,000)(2,000)
Other7 7 (11)(4)
Balance, October 2, 20229,515 $476 $91,359 (3,903)$(113,945)$122,967 $(8,225)$92,631 $259 $92,891
See Accompanying Notes.
PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)
Nine Months Ended
(MILLIONS)October 1,
2023October 2,
2022
Operating Activities
Net income before allocation to noncontrolling interests$5,518 $26,404
Discontinued operations net of tax11 4
Net income from continuing operations before allocation to noncontrolling interests5,507 26,400
Adjustments to reconcile net income before allocation to noncontrolling interests to net cash provided by/(used in) operating activities:
Depreciation and amortization4,620 3,545
Asset write-offs and impairments499 287
Deferred taxes(1,584)(3,399)
Share-based compensation expense404 508
Benefit plan contributions in excess of expense/income(467)(532)
Inventory write-offs and related charges associated with COVID-19 products(a)
5,847 476
Other adjustments, net(744)1,481
Other changes in assets and liabilities, net of acquisitions and divestitures(10,622)(8,081)
Net cash provided by/(used in) operating activities3,460 20,685
Investing Activities
Purchases of property, plant and equipment(2,863)(2,235)
Purchases of short-term investments(30,138)(29,701)
Proceeds from redemptions/sales of short-term investments18,018 35,087
Net (purchases of)/proceeds from redemptions/sales of short-term investments with original maturities of three months or less(6,102)(10,877)
Purchases of long-term investments(166)(1,627)
Proceeds from redemptions/sales of long-term investments189 446
Acquisitions of businesses, net of cash acquired(25)(6,225)
Dividend received from the Consumer Healthcare JV
3,960
Other investing activities, net(193)(200)
Net cash provided by/(used in) investing activities(21,282)(11,373)
Financing Activities
Proceeds from short-term borrowings14 3,887
Payments on short-term borrowings (3,887)
Net (payments on)/proceeds from short-term borrowings with original maturities of three months or less
(106)870
Proceeds from issuance of long-term debt30,831
Payments on long-term debt(2,569)(1,609)
Purchases of common stock (2,000)
Cash dividends paid(6,932)(6,738)
Other financing activities, net(613)(342)
Net cash provided by/(used in) financing activities20,624 (9,819)
Effect of exchange-rate changes on cash and cash equivalents and restricted cash and cash equivalents
(39)(139)
Net increase/(decrease) in cash and cash equivalents and restricted cash and cash equivalents2,764 (646)
Cash and cash equivalents and restricted cash and cash equivalents, at beginning of period468 1,983
Cash and cash equivalents and restricted cash and cash equivalents, at end of period$3,233 $1,338
Supplemental Cash Flow Information
Cash paid during the period for:
Income taxes
$2,907 $4,919
Interest paid
1,153 1,121
Interest rate hedges98 28
(a) See Notes 8 and 13.
See Accompanying Notes.
PFIZER INC. AND SUBSIDIARY COMPANIES.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
Note 1. Basis of Presentation and Significant Accounting Policies
A. Basis of Presentation
We prepared these condensed consolidated financial statements in conformity with U.S. GAAP, consistent in all material respects with those applied in our 2022 Form 10-K. As permitted under the SEC requirements for interim reporting, certain footnotes or other financial information have been condensed or omitted.
These financial statements include all normal and recurring adjustments that are considered necessary for the fair statement of results for the interim periods presented. The information included in this Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying notes included in our 2022 Form 10-K. Revenues, expenses, assets and liabilities can vary during each quarter of the year. Therefore, the results and trends in these interim financial statements may not be representative of those for the full year.
Pfizer s fiscal quarter-end for subsidiaries operating outside the U.S. is as of and for the three and nine months ended August 27, 2023 and August 28, 2022, and for U.S. subsidiaries is as of and for the three and nine months ended October 1, 2023 and October 2, 2022.
We manage our commercial operations through two operating segments, each led by a single manager: Biopharma and Business Innovation. Biopharma is the only reportable segment. See Note 13A below and Note 17A in our 2022 Form 10-K.
Business development activities impacted financial results in the periods presented. In March 2023, we and Seagen announced that the companies entered into an agreement under which we will acquire Seagen, a global biotechnology company that discovers, develops and commercializes transformative cancer medicines, for $229 in cash per Seagen share for a total enterprise value of approximately $43 billion. We expect to finance the transaction substantially through $31 billion of long-term debt issued in May 2023 (see Note 7D), and the balance from a combination of short-term financing and existing cash. The transaction was approved by Seagen s shareholders in May 2023. In October 2023, we received unconditional antitrust clearance from the EC on the proposed acquisition. The transaction is expected to close in late 2023 or early 2024, and remains subject to customary closing conditions, including receipt of required regulatory approvals. See Note 2 below, as well as Notes 1A and 2 in our 2022 Form 10-K.
We have made certain reclassification adjustments to conform prior-period amounts to the current presentation for segment reporting.
B. New Accounting Standards Adopted in 2023
On January 1, 2023, we adopted a new accounting standard for supplier finance programs which requires increased disclosures in the notes to our financial statements. See Note 8C.
In the second quarter of 2023, we adopted new accounting standards on reference rate reform that provide temporary optional expedients and exceptions to the guidance for contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate that were discontinued after June 30, 2023. We applied certain of the optional expedients related to hedge accounting relationships. The main purpose of the expedients is to allow hedge accounting to continue uninterrupted and make it easier to apply the requirements to maintain hedge accounting during the transition period through December 31, 2024.
C. Revenues and Trade Accounts Receivable
Customers Our prescription biopharmaceutical products, with the exception of Paxlovid, are sold principally to wholesalers, but we also sell directly to retailers, hospitals, clinics, government agencies and pharmacies. We principally sell Paxlovid to government agencies and distributors. In the U.S., we primarily sell our vaccines directly to the federal government (including the CDC), wholesalers, individual provider offices, retail pharmacies and integrated delivery systems. Outside the U.S., we primarily sell our vaccines to government and non-government institutions.
10
PFIZER INC. AND SUBSIDIARY COMPANIES.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
Deductions from Revenues Our accruals for Medicare, Medicaid and related state program and performance-based contract rebates, chargebacks, sales allowances and sales returns and cash discounts are as follows:
(MILLIONS)October 1,
2023December 31, 2022
Reserve against Trade accounts receivable, less allowance for doubtful accounts
$1,599 $1,200
Other current liabilities:
Accrued rebates5,083 4,479
Other accruals436 430
Other noncurrent liabilities
640 612
Total accrued rebates and other sales-related accruals$7,757 $6,722
Trade Accounts Receivable Trade accounts receivable are stated at their net realizable value. The allowance for credit losses reflects our best estimate of expected credit losses of the receivables portfolio determined on the basis of historical experience, current information, and forecasts of future economic conditions. In developing the estimate for expected credit losses, trade accounts receivables are segmented into pools of assets depending on market (U.S. versus international), delinquency status, and customer type (high risk versus low risk and government versus non-government), and fixed reserve percentages are established for each pool of trade accounts receivables.
In determining the reserve percentages for each pool of trade accounts receivables, we considered our historical experience with certain customers and customer types, regulatory and legal environments, country and political risk, and other relevant current and future forecasted macroeconomic factors. When management becomes aware of certain customer-specific factors that impact credit risk, specific allowances for these known troubled accounts are recorded.
During the three and nine months ended October 1, 2023 and October 2, 2022, additions to the allowance for credit losses, write-offs and recoveries of customer receivables were not material to our condensed consolidated financial statements. For additional information on our trade accounts receivable, see Note 1G in our 2022 Form 10-K.
Note 2. Acquisitions, Divestitures, Equity-Method Investment and Research and Development Arrangement
A. Acquisitions
GBT On October 5, 2022, we acquired GBT, a biopharmaceutical company dedicated to the discovery, development and delivery of life-changing treatments for underserved patient communities, starting with sickle cell disease. The total fair value of the consideration transferred was $5.7 billion ($5.2 billion, net of cash acquired). In connection with this business combination, we provisionally recorded: (i) $4.4 billion in Identifiable intangible assets, consisting of $3.0 billion of IPR&D and $1.4 billion of developed technology rights with a useful life of six years, (ii) $1.0 billion of Goodwill, (iii) $672 million of inventories to be sold over approximately three years, (iv) $523 million of net deferred tax liabilities and (v) $331 million of assumed long-term debt that was paid in full in the fourth quarter of 2022. The allocation of the consideration transferred to the assets acquired and liabilities assumed has not yet been finalized.
Biohaven On October 3, 2022, we acquired Biohaven, the maker of Nurtec ODT/Vydura (rimegepant), an innovative therapy approved for both acute treatment of migraine and prevention of episodic migraine in adults. The total fair value of the consideration transferred was $11.8 billion, which includes the fair value of Pfizer s previous investment in Biohaven on the acquisition date of approximately $300 million. In connection with this business combination, we provisionally recorded: (i) $12.1 billion in Identifiable intangible assets, consisting of $11.6 billion of developed technology rights with a useful life of 11 years and $450 million of IPR&D, (ii) $828 million of Goodwill, (iii) $813 million of inventories to be sold over approximately two years, (iv) $398 million of trade accounts receivable, (v) $1.4 billion of assumed long-term debt that was paid in full in the fourth quarter of 2022, (vi) $550 million of net deferred tax liabilities and (vii) $526 million of Other current liabilities. The allocation of the consideration transferred to the assets acquired and liabilities assumed has not yet been finalized.
Arena On March 11, 2022, we acquired Arena, a clinical stage company with development-stage therapeutic candidates in gastroenterology, dermatology and cardiology. The total fair value of the consideration transferred was $6.6 billion ($6.2 billion, net of cash acquired). The final allocation of the consideration transferred to the assets acquired and the liabilities assumed was completed in the first quarter of 2023. In connection with this business combination, we recorded: (i) $5.5 billion in Identifiable intangible assets, consisting of $5.0 billion of IPR&D and $460 million of indefinite-lived licensing agreements and other, (ii) $1.0 billion of Goodwill and (iii) $490 million of net deferred tax liabilities.
B. Divestitures
Divestiture of Early-Stage Rare Disease Gene Therapy Portfolio On September 19, 2023, we completed an agreement with Alexion, under which Alexion purchased and licensed the assets of our early-stage rare disease gene therapy portfolio. This agreement is consistent with our previously announced strategy to pivot from viral capsid-based gene therapy approaches to
11
PFIZER INC. AND SUBSIDIARY COMPANIES.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
harnessing new platform technologies that we believe can have a transformative impact on patients, such as mRNA or in vivo gene editing. Under the terms of the agreement, Alexion will pay us total consideration of up to $1 billion, consisting of an upfront payment of $300 million paid at closing and future contingent milestone payments, plus tiered royalties based on annual net sales of the assets. In connection with the closing of the transaction, Pfizer recognized a $222 million pre-tax gain in Other (income)/deductions net (see Note 4).
Discontinued operations net of tax in the periods presented relate to post-close adjustments for previously divested businesses that were classified as discontinued operations. In the three and nine months ended October 1, 2023 and October 2, 2022, amounts recorded under interim agreements, including TSAs and MSAs, associated with these disposals were not material. Under agreements related to the 2020 spin-off and the combination of the Upjohn Business with Mylan to form Viatris, net amounts due to Viatris were $31 million as of October 1, 2023 and $94 million as of December 31, 2022. The cash flows associated with the agreements are included in Net cash provided by/(used in) operating activities. For information about the nature of these agreements, see Note 2B in our 2022 Form 10-K.
C. Equity-Method Investment
Haleon/Consumer Healthcare JV On July 18, 2022, GSK completed a demerger of the Consumer Healthcare JV which became Haleon, an independent, publicly traded company listed on the London Stock Exchange that holds the joint historical consumer healthcare business of GSK and Pfizer following the demerger. We continue to own 32% of the ordinary shares of Haleon after the demerger.
The carrying value of our investment in Haleon was $10.8 billion as of both October 1, 2023 and December 31, 2022, and is reported in Equity-method investments. The fair value of our investment in Haleon as of October 1, 2023, based on quoted market prices of Haleon stock, was $12.3 billion. Haleon/the Consumer Healthcare JV is a foreign investee whose reporting currency is the U.K. pound, and therefore we translate its financial statements into U.S. dollars and recognize the impact of foreign currency translation adjustments in the carrying value of our investment and in other comprehensive income. The value of our investment was effectively unchanged during the first nine months of 2023, primarily due to our share of Haleon s earnings of $341 million, partially offset by $183 million in pre-tax foreign currency translation adjustments (see Note 6) and $154 million in dividends. We record our share of earnings from Haleon/the Consumer Healthcare JV on a quarterly basis on a one-quarter lag in Other (income)/deductions net. Our total share of Haleon s earnings generated in the second quarter of 2023, which we recorded in our operating results in the third quarter of 2023, was $122 million. Our total share of Haleon s earnings generated in the fourth quarter of 2022 and first six months of 2023, which we recorded in our operating results in the first nine months of 2023, was $341 million. Our total share of the JV s earnings generated in the second quarter of 2022, which we recorded in our operating results in the third quarter of 2022, was $67 million. Our total share of the JV s earnings generated in the fourth quarter of 2021 and first six months of 2022, which we recorded in our operating results in the first nine months of 2022, was $402 million. In the third quarter and first nine months of 2022, our equity-method income included in Other (income)/deductions net also included charges of $118 million and $119 million, respectively, primarily for adjustments to our equity-method basis differences related to the separation of Haleon/the Consumer Healthcare JV from GSK. The total amortization and adjustment of basis differences resulting from the excess of the initial fair value of our investment over the underlying equity in the carrying value of the net assets of Haleon/the Consumer Healthcare JV was not material to our results of operations in the third quarter and first nine months of 2023. See Note 4.
Summarized financial information for our equity-method investee, Haleon/the Consumer Healthcare JV, for the three and nine months ending June 30, 2023, the most recent period available, and for the three and nine months ending June 30, 2022, is as follows:
Three Months EndedNine Months Ended
(MILLIONS)June 30,
2023June 30,
2022June 30,
2023June 30,
2022
Net sales$3,490 $3,218 $10,379 $10,164
Cost of sales(1,323)(1,196)(4,211)(3,830)
Gross profit$2,167 $2,022 $6,168 $6,334
Income from continuing operations403 226 1,133 1,303
Net income403 226 1,133 1,303
Income attributable to shareholders382 210 1,066 1,256
12
PFIZER INC. AND SUBSIDIARY COMPANIES.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
D. Research and Development Arrangement
Research and Development Funding Arrangement with Blackstone In April 2023, we entered into an arrangement with Blackstone under which we will receive up to a total of $550 million in 2023 through 2026 to co-fund our quarterly development costs for specified treatments. As there is substantive transfer of risk to the financial partner, the development funding is recognized by us as an obligation to perform contractual services. We are recognizing the funding as a reduction of Research and development expenses using an attribution model over the period of the related expenses. The reduction to Research and development expenses for the third quarter and first nine months of 2023 was $43 million and $88 million, respectively. If successful, upon regulatory approval in the U.S. or certain major markets in the EU for the indications based on the applicable clinical trials, Blackstone will be eligible to receive approval-based fixed milestone payments of up to $468 million contingent upon the successful results of the clinical trials. Fixed milestone payments due upon approval will be recorded as intangible assets and amortized to Amortization of intangible assets over the shorter of the term of the agreement or estimated commercial life of the product. Following potential regulatory approval, Blackstone will be eligible to receive a combination of fixed milestone payments of up to $550 million in total based on achievement of certain levels of cumulative applicable net sales, as well as royalties based on a mid-to-high single digit percentage of the applicable net sales. Fixed sales-based milestone payments will be recorded as intangible assets and amortized to Amortization of intangible assets over the shorter of the term of the agreement or estimated commercial life of the product, and royalties on net sales will be recorded as Cost of sales when incurred.
Note 3. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives
A. Transforming to a More Focused Company Program
In 2019, we announced that we would be incurring costs associated with our Transforming to a More Focused Company Program, a multi-year effort to ensure our cost base aligns appropriately with our operating structure following Pfizer s transformation into a more focused, innovative science-based global biopharmaceutical business. This program includes activities to (i) restructure our corporate enabling functions to appropriately support our operating structure; (ii) transform our commercial go-to-market model; and (iii) optimize our manufacturing network and R&D operations.
The activities associated with transforming our commercial go-to-market model are substantially complete. Activities associated with restructuring our corporate enabling functions and optimizing our manufacturing network and R&D operations are ongoing and are expected to be substantially completed by the end of 2023. The costs to restructure our corporate enabling functions, and to optimize our R&D operations and reduce cycle times, as well as to further prioritize our internal R&D portfolio, primarily include severance and implementation costs. The costs to optimize our manufacturing network largely include severance, implementation costs, product transfer costs, site exit costs, and accelerated depreciation.
From the start of this program in the fourth quarter of 2019 through October 1, 2023, we incurred costs of $3.9 billion, of which $1.5 billion ($1.1 billion of restructuring charges) is associated with Biopharma. We have incurred approximately 90% of total expected costs to date, and we expect the remaining costs to be substantially incurred through 2023.
13
PFIZER INC. AND SUBSIDIARY COMPANIES.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
B. Key Activities
The following summarizes costs and credits for acquisitions and cost-reduction/productivity initiatives:
Three Months EndedNine Months Ended
(MILLIONS)October 1,
2023October 2,
2022October 1,
2023October 2,
2022
Restructuring charges/(credits):
Employee terminations$16 $158 $77 $293
Asset impairments40 17 45 44
Exit costs/(credits)15 2 44 31
Restructuring charges/(credits)(a)
71 177 165 368
Transaction costs(b)
5 14 42
Integration/pre-integration costs and other(c)
78 22 198 170
Restructuring charges and certain acquisition-related costs155 199 377 580
Net periodic benefit costs/(credits) recorded in Other (income)/deductions net
(7)(5)
Additional depreciation asset restructuring recorded in our condensed consolidated statements of operations, mainly in Cost of sales(d)
5 7 28 22
Implementation costs recorded in our condensed consolidated statements of operations as follows(e):
Cost of sales16 14 43 40
Selling, informational and administrative expenses71 136 196 344
Research and development expenses29 59
Total implementation costs116 150 298 384
Total costs associated with acquisitions and cost-reduction/productivity initiatives$276 $357 $696 $982
(a)Primarily represents cost-reduction initiatives. Restructuring charges/(credits) associated with Biopharma: charges of $1 million and credits of $22 million for the three and nine months ended October 1, 2023, respectively, and charges of $62 million and $108 million for the three and nine months ended October 2, 2022, respectively.
(b)Represents external costs for banking, legal, accounting and other similar services.
(c)Represents external, incremental costs directly related to integrating acquired businesses and our proposed acquisition of Seagen, such as expenditures for consulting and the integration of systems and processes, and certain other qualifying costs. In the nine months ended October 1, 2023, integration/pre-integration costs and other were mostly related to our acquisitions of Biohaven and GBT and our proposed acquisition of Seagen. In the nine months ended October 2, 2022, integration costs and other were mostly related to our acquisition of Arena, including $138 million in payments to Arena employees in the first quarter of 2022 for the fair value of previously unvested long-term incentive awards that was recognized as post-closing compensation expense.
(d)Represents the impact of changes in the estimated useful lives of assets involved in restructuring actions.
(e)Represents external, incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives.
The following summarizes the components and changes in restructuring accruals:
(MILLIONS)Employee
Termination
CostsAsset
Impairment
ChargesExit CostsAccrual
Balance, December 31, 2022(a)
$1,196 $ $8 $1,204
Provision/(credit)77 45 44 165
Utilization and other(b)
(700)(45)(39)(784)
Balance, October 1, 2023(c)
$573 $ $12 $585
(a)Included in Other current liabilities ($991 million) and Other noncurrent liabilities ($213 million).
(b)Other activity includes adjustments for foreign currency translation that are not material.
(c)Included in Other current liabilities ($447 million) and Other noncurrent liabilities ($137 million).
14
PFIZER INC. AND SUBSIDIARY COMPANIES.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
Note 4. Other (Income)/Deductions Net
Components of Other (income)/deductions net include:
Three Months EndedNine Months Ended
(MILLIONS)October 1,
2023October 2,
2022October 1,
2023October 2,
2022
Interest income$(523)$(70)$(1,015)$(114)
Interest expense695 311 1,521 925
Net interest expense(a)
173 240 505 811
Royalty-related income(260)(239)(737)(628)
Net (gains)/losses on asset disposals 7 (2)6
Net (gains)/losses recognized during the period on equity securities(b)
393 112 709 1,353
Income from collaborations, out-licensing arrangements and sales of compound/product rights(10)(4)(84)(17)
Net periodic benefit costs/(credits) other than service costs(92)(306)(260)(294)
Certain legal matters, net(c)
71 77 246 175
Certain asset impairments(d)
200 264 200
Haleon/Consumer Healthcare JV equity method (income)/loss(e)
(131)51 (354)(283)
Other, net(f)
(222)(198)(643)(260)
Other (income)/deductions net$(79)$(59)$(356)$1,063
(a)The decrease in net interest expense in the third quarter and first nine months of 2023 reflects higher interest expense driven by our $31 billion aggregate principal amount of senior unsecured notes issued in May 2023 as part of the financing for our proposed acquisition of Seagen, which was more than offset by higher interest income on the investment of the net proceeds from the debt issuance.
(b)The net losses in the third quarter of 2023 include, among other things, unrealized losses of $312 million related to our investments in Cerevel Therapeutics Holdings, Inc. (Cerevel) and Allogene Therapeutics, Inc (Allogene). The net losses in the first nine months of 2023 include, among other things, unrealized losses of $606 million related to our investments in BioNTech, Cerevel and Allogene. The net losses in the first nine months of 2022 included, among other things, unrealized losses of $974 million related to our investments in BioNTech, Cerevel and Arvinas.
(c)The third quarter of 2023 includes legal obligations related to pre-acquisition matters and certain product liability expenses related to products discontinued and/or divested by Pfizer. The first nine months of 2023 primarily includes certain product liability and other legal expenses related to products discontinued and/or divested by Pfizer and legal obligations related to pre-acquisition matters. The third quarter and first nine months of 2022 primarily included certain product liability and other legal expenses related to products discontinued and/or divested by Pfizer.
(d)The first nine months of 2023 primarily represents intangible asset impairment charges, including $128 million associated with Other business activities, related to IPR&D and developed technology rights for acquired software assets and reflects unfavorable pivotal trial results and updated commercial forecasts, and $120 million associated with our Biopharma segment resulting from the discontinuation of a study related to an out-licensed IPR&D asset for the treatment of prostate cancer, acquired in our Array BioPharma Inc. (Array) acquisition. The third quarter and first nine months of 2022 represented an intangible asset impairment charge associated with our Biopharma segment, representing an IPR&D asset for the unapproved indication of symptomatic dilated cardiomyopathy due to a mutation of the gene encoding the lamin A/C protein, acquired in our Array acquisition, and was a result of the Phase 3 trial reaching futility at a pre-planned interim analysis.
(e)See Note 2C.
(f)The third quarter and first nine months of 2023 includes, among other things, a $222 million gain on the divestiture of our early-stage rare disease gene therapy portfolio to Alexion. The first nine months of 2023 also includes, among other things, dividend income of $213 million from our investment in ViiV and $211 million from our investment in Nimbus resulting from Takeda Pharmaceutical Company Limited s acquisition of Nimbus s oral, selective allosteric tyrosine kinase 2 (TYK2) inhibitor program subsidiary.
Additional information about the intangible assets that were impaired during 2023 follows:
Nine Months Ended
Fair Value(a)
October 1, 2023
(MILLIONS)AmountLevel 1Level 2Level 3Impairment
Intangible assets Licensing agreements and other(b)
$ $ $ $ $120
Intangible assets IPR&D(b)
94
Intangible assets Developed technology rights(b)
34
Total$ $ $ $ $248
(a)The fair value amount is presented as of the date of impairment, as this asset is not measured at fair value on a recurring basis. See also Note 1E in our 2022 Form 10-K.
(b)Reflects intangible assets written down to fair value in 2023. Fair value was determined using the income approach, specifically the multi-period excess earnings method, also known as the discounted cash flow method. We started with a forecast of all the expected net cash flows for the asset and then applied an asset-specific discount rate to arrive at a net present value amount. Some of the more significant estimates and assumptions inherent in this approach
15
PFIZER INC. AND SUBSIDIARY COMPANIES.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
include: the amount and timing of the projected net cash flows, which includes the expected impact of competitive, legal and/or regulatory forces on the product; the discount rate, which seeks to reflect the various risks inherent in the projected cash flows; and the tax rate, which seeks to incorporate the geographic diversity of the projected cash flows.
Note 5. Tax Matters
A. Taxes on Income/(Loss) from Continuing Operations
Our effective tax rate for continuing operations was 28.8% for the third quarter of 2023, compared to 4.0% for the third quarter of 2022, and was (6.2)% for the first nine months of 2023, compared to 10.5% for the first nine months of 2022. The positive effective tax rate for the third quarter of 2023 reflects a tax benefit on a pre-tax loss primarily resulting from changes in forecast and jurisdictional mix of earnings. The tax benefit for the third quarter of 2023 and the negative effective tax rate for the first nine months of 2023, compared to the tax provisions for the third quarter and first nine months of 2022, were primarily due to changes in forecast and jurisdictional mix of earnings. The tax provisions for the third quarter and first nine months of 2022 also included tax benefits related to global income tax resolutions in multiple tax jurisdictions spanning multiple tax years that included the closing of U.S. Internal Revenue Service audits covering five tax years.
We elected, with the filing of our 2018 U.S. Federal Consolidated Income Tax Return, to pay our initial estimated $15 billion repatriation tax liability on accumulated post-1986 foreign earnings over eight years through 2026. The fifth annual installment of this liability was paid by its April 18, 2023 due date. The sixth annual installment is due April 15, 2024 and is reported in current Income taxes payable as of October 1, 2023. The remaining liability is reported in noncurrent Other taxes payable. Our obligations may vary as a result of changes in our uncertain tax positions and/or availability of attributes such as foreign tax and other credit carryforwards.
B. Tax Contingencies
We are subject to income tax in many jurisdictions, and a certain degree of estimation is required in recording the assets and liabilities related to income taxes. All of our tax positions are subject to audit by the local taxing authorities in each tax jurisdiction. These tax audits can involve complex issues, interpretations and judgments and the resolution of matters may span multiple years, particularly if subject to negotiation or litigation.
The U.S. is one of our major tax jurisdictions, and we are regularly audited by the IRS. With respect to Pfizer, tax years 2016-2018 are under audit. Tax years 2019-2023 are open but not under audit. All other tax years are closed. In addition to the open audit years in the U.S., we have open audit years and certain related audits, appeals and investigations in certain major international tax jurisdictions dating back to 2012.
See Note 5D in our 2022 Form 10-K.
C. Tax Provision/(Benefit) on Other Comprehensive Income/(Loss)
Components of Tax provision/(benefit) on other comprehensive income/(loss) include:
Three Months EndedNine Months Ended
(MILLIONS)October 1,
2023October 2,
2022October 1,
2023October 2,
2022
Foreign currency translation adjustments, net(a)
$(28)$20 $(33)$(165)
Unrealized holding gains/(losses) on derivative financial instruments, net80 47 108 177
Reclassification adjustments for (gains)/losses included in net income/(loss)
(5)(72)(16)(97)
75 (25)91 80
Unrealized holding gains/(losses) on available-for-sale securities, net(10)(97)4 (175)
Reclassification adjustments for (gains)/losses included in net income/(loss)
6 76 (55)137
(4)(21)(51)(38)
Reclassification adjustments related to amortization of prior service costs and other, net(7)(7)(21)(23)
Reclassification adjustments related to curtailments of prior service costs and other, net(1) (3)(3)
(7)(8)(24)(26)
Tax provision/(benefit) on other comprehensive income/(loss)$36 $(33)$(17)$(149)
(a)Taxes are not provided for foreign currency translation adjustments relating to investments in international subsidiaries that we intend to hold indefinitely.
16
PFIZER INC. AND SUBSIDIARY COMPANIES.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
Note 6. Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests
The following summarizes the changes, net of tax, in Accumulated other comprehensive loss:
Net Unrealized Gains/(Losses)Benefit Plans
(MILLIONS)Foreign Currency Translation Adjustments(a)
Derivative Financial InstrumentsAvailable-For-Sale SecuritiesPrior Service (Costs)/Credits and OtherAccumulated Other Comprehensive Income/(Loss)
Balance, December 31, 2022
$(8,360)$(412)$220 $248 $(8,304)
Other comprehensive income/(loss)(b)
274 501 (360)(78)338
Balance, October 1, 2023$(8,086)$89 $(140)$170 $(7,966)
(a)Amounts do not include foreign currency translation adjustments attributable to noncontrolling interests.
(b)Foreign currency translation adjustments include net losses related to our equity-method investment in Haleon (see Note 2C) and the impact of our net investment hedging program.
17
PFIZER INC. AND SUBSIDIARY COMPANIES.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
Note 7. Financial Instruments
A. Fair Value Measurements
Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis and Fair Value Hierarchy, using a Market Approach:
October 1, 2023December 31, 2022
(MILLIONS)TotalLevel 1Level 2TotalLevel 1Level 2
Financial assets:
Short-term investments
Equity securities with readily determinable fair values:
Money market funds$13,193 $ $13,193 $1,588 $ $1,588
Available-for-sale debt securities:
Government and agency non-U.S.
18,236 18,236 15,915 15,915
Government and agency U.S.
5,832 5,832 1,313 1,313
Corporate and other
2,179 2,179 1,514 1,514
26,247 26,247 18,743 18,743
Total short-term investments39,440 39,440 20,331 20,331
Other current assets
Derivative assets:
Interest rate contracts
1 1
Foreign exchange contracts
712 712 714 714
Total other current assets713 713 714 714
Long-term investments
Equity securities with readily determinable fair values(a)
2,118 2,112 6 2,836 2,823 13
Available-for-sale debt securities:
Government and agency non-U.S.
138 138 280 280
Corporate and other
73 73 72 72
211 211 352 352
Total long-term investments2,329 2,112 217 3,188 2,823 365
Other noncurrent assets
Derivative assets:
Interest rate contracts
1 1
Foreign exchange contracts
413 413 364 364
Total derivative assets414 414 364 364
Insurance contracts(b)
718 718 665 665
Total other noncurrent assets1,132 1,132 1,028 1,028
Total assets$43,613 $2,112 $41,501 $25,261 $2,823 $22,439
Financial liabilities:
Other current liabilities
Derivative liabilities:
Interest rate contracts$4 $ $4 $10 $ $10
Foreign exchange contracts
193 193 694 694
Total other current liabilities197 197 704 704
Other noncurrent liabilities
Derivative liabilities:
Interest rate contracts533 533 321 321
Foreign exchange contracts
738 738 864 864
Total other noncurrent liabilities1,270 1,270 1,185 1,185
Total liabilities$1,468 $ $1,468 $1,889 $ $1,889
(a)Long-term equity securities of $127 million as of October 1, 2023 and $143 million as of December 31, 2022 were held in restricted trusts for U.S. non-qualified employee benefit plans.
(b)Includes life insurance policies held in restricted trusts for U.S. non-qualified employee benefit plans. The underlying invested assets in these contracts are marketable securities, which are carried at fair value, with changes in fair value recognized in Other (income)/deductions net (see Note 4).
Financial Assets and Liabilities Not Measured at Fair Value on a Recurring Basis The carrying value of Long-term debt, excluding the current portion, was $61 billion as of October 1, 2023 and $33 billion as of December 31, 2022. The estimated fair value of such debt, using a market approach and Level 2 inputs, was $57 billion as of October 1, 2023 and $30 billion as of December 31, 2022.
18
PFIZER INC. AND SUBSIDIARY COMPANIES.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
The differences between the estimated fair values and carrying values of held-to-maturity debt securities, private equity securities, long-term receivables and short-term borrowings not measured at fair value on a recurring basis were not significant as of October 1, 2023 and December 31, 2022. The fair value measurements of our held-to-maturity debt securities and short-term borrowings are based on Level 2 inputs. The fair value measurements of our long-term receivables and private equity securities are based on Level 3 inputs.
B. Investments
Total Short-Term, Long-Term and Equity-Method Investments
The following summarizes our investments by classification type:
(MILLIONS)October 1,
2023 December 31, 2022
Short-term investments
Equity securities with readily determinable fair values(a)
$13,193 $1,588
Available-for-sale debt securities26,247 18,743
Held-to-maturity debt securities1,593 1,985
Total Short-term investments$41,033 $22,316
Long-term investments
Equity securities with readily determinable fair values(b)
$2,118 $2,836
Available-for-sale debt securities211 352
Held-to-maturity debt securities50 48
Private equity securities at cost(b)
834 800
Total Long-term investments$3,214 $4,036
Equity-method investments11,025 11,033
Total long-term investments and equity-method investments$14,239 $15,069
Held-to-maturity cash equivalents$384 $679
(a)Represent money market funds primarily invested in U.S. Treasury and government debt.
(b)Represent investments in the life sciences sector.
Debt Securities
Our investment portfolio consists of investment-grade debt securities issued across diverse governments, corporate and financial institutions:
October 1, 2023December 31, 2022
Gross UnrealizedContractual or Estimated Maturities (in Years)Gross Unrealized
(MILLIONS)Amortized CostGainsLossesFair ValueWithin 1Over 1
to 5Over 5Amortized CostGainsLossesFair Value
Available-for-sale debt securities
Government and agency non-U.S.
$18,528 $16 $(170)$18,374 $18,236 $138 $ $15,946 $297 $(48)$16,195
Government and agency U.S.
5,833 (1)5,832 5,832 1,313 1,313
Corporate and other2,257 (6)2,252 2,179 73 1,584 7 (4)1,586
Held-to-maturity debt securities
Time deposits and other
944 944 898 35 11 1,171 1,171
Government and agency non-U.S.
1,084 1,084 1,080 3 1 1,542 1,542
Total debt securities$28,646 $16 $(176)$28,486 $28,225 $249 $12 $21,556 $304 $(53)$21,807
Any expected credit losses to these portfolios would be immaterial to our financial statements.
19
PFIZER INC. AND SUBSIDIARY COMPANIES.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
Equity Securities
The following presents the calculation of the portion of unrealized (gains)/losses that relates to equity securities, excluding equity-method investments, held at the reporting date: